Lasofoxifene

Drug Profile

Lasofoxifene

Alternative Names: CP-336156; CP-336156-CB; Fablyn; Lasofoxifene tartrate; Oporia

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals; Pfizer
  • Developer Pfizer; Sermonix Pharmaceuticals
  • Class Antineoplastics; Osteoporosis therapies; Pyrrolidines; Small molecules; Tetrahydronaphthalenes
  • Mechanism of Action Estrogen receptor agonists; Estrogen receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Postmenopausal osteoporosis
  • Preregistration Atrophic vaginitis
  • Phase III Breast cancer
  • Phase II Female sexual dysfunction
  • Research Ovarian cancer
  • No development reported Hypogonadism

Most Recent Events

  • 03 Mar 2017 No development reported - Phase-I for Hypogonadism (In volunteers) in USA (PO) (Sermonix Pharmaceuticals pipeline, March 2017)
  • 28 Feb 2017 Lasofoxifene licensed to Sermonix Pharmaceuticals worldwide
  • 28 Feb 2017 Sermonix Pharmaceuticals plans a phase II trial for Breast cancer (Late-stage disease, Metastatic disease) in Europe and USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top